Dual inhibitors of <i>Pseudomonas aeruginosa</i> virulence factors LecA and LasB-Reference-Cited by-同舟云学术

Dual inhibitors of Pseudomonas aeruginosa virulence factors LecA and LasB

Published:2024 Issue:33 Volume:15 Page:13333-13342
ISSN:2041-6520
Container-title:Chemical Science
language:en
Short-container-title:Chem. Sci.

Author:

Metelkina Olga¹²³^ORCID,Konstantinović Jelena¹^ORCID,Klein Andreas¹⁴,Shafiei Roya¹⁴,Fares Mario¹²³,Alhayek Alaa¹,Yahiaoui Samir¹,Elgaher Walid A. M.¹^ORCID,Haupenthal Jörg¹^ORCID,Titz Alexander¹²³^ORCID,Hirsch Anna K. H.¹²⁴^ORCID

Affiliation:

1. Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Campus E8.1, 66123 Saarbrücken, Germany

2. Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hannover – Braunschweig, 38124 Braunschweig, Germany

3. Department of Chemistry, Saarland University, 66123 Saarbrücken, Germany

4. Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany

Abstract

Dual inhibitors of two key virulence factors of Pseudomonas aeruginosa, the lectin LecA and the protease LasB, open up an opportunity in the current antimicrobial-resistance crisis.

Funder

Helmholtz-Gemeinschaft

Alexander von Humboldt-Stiftung

European Research Council

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/SC/D4SC02703E

Reference54 articles.

1. Towards the sustainable discovery and development of new antibiotics

2. Disarming pathogens: benefits and challenges of antimicrobials that target bacterial virulence instead of growth and viability

3. Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infections

4. Targeting virulence: a new paradigm for antimicrobial therapy

5. Fighting antibiotic resistance—strategies and (pre)clinical developments to find new antibacterials